Pioneers FAQ

Perhaps de Grey's most famous concept is Longevity Escape Velocity (LEV). The idea is elegantly simple: if medical technology can extend healthy human lifespan by even a few decades, that additional time provides the opportunity to benefit from further advances in rejuvenation medicine. At some point, the rate of medical progress outpaces the rate of biological aging, and life expectancy begins to increase by more than one year for every year that passes. At that point, people effectively stop aging -- not because a single magic bullet has been found, but because successive generations of therapies keep pushing the horizon further.

Church's ventures continue to push boundaries. Colossal Biosciences, which he co-founded, secured $200 million in Series C funding in January 2025, reaching a $10.2 billion valuation — making it Texas' first decacorn. In April 2025, the company announced the birth of three genetically modified "dire wolf" pups with 20 gene edits matching ancient dire wolf DNA, including pale coat coloring. The company also acquired ViaGen Pets (animal cloning) and expanded internationally by acquiring the TIGRR Lab at the University of Melbourne for thylacine (Tasmanian tiger) de-extinction.

In 2012, just six years after his initial publication, Yamanaka shared the Nobel Prize in Physiology or Medicine with Sir John Gurdon, the British developmental biologist who had shown in 1962 that the nucleus of a differentiated frog cell could be reprogrammed by transplanting it into an enucleated egg. Gurdon's work had established that differentiation did not involve permanent loss of genetic information; Yamanaka's work identified the specific factors that could reverse it. Together, their discoveries overturned decades of biological orthodoxy.

David Andrew Sinclair was born in 1969 in Sydney, Australia. His parents were Hungarian immigrants who had fled communist rule, and Sinclair has spoken about how their experiences shaped his drive and resilience. He studied biochemistry at the University of New South Wales, where he became interested in the molecular biology of aging. His PhD research focused on the genetics of yeast aging, specifically how repetitive ribosomal DNA sequences accumulate as extrachromosomal circles in aging yeast cells, contributing to cellular senescence.

After completing his PhD, Zhang joined the Broad Institute and MIT as a fellow, quickly establishing his own laboratory. By 2011, he had become aware of the CRISPR-Cas system, a bacterial immune defense mechanism that could be repurposed for genome editing. While Jennifer Doudna and Emmanuelle Charpentier had demonstrated in their landmark June 2012 Science paper that CRISPR-Cas9 could cut DNA in a test tube, the critical next step was proving the system could work inside the complex environment of human and other mammalian cells.

In 2017, Blackburn and Epel published "The Telomere Effect," a book aimed at a general audience that synthesized decades of research into practical advice. The book explored how diet, exercise, sleep, social connections, and stress management can influence telomere maintenance. While some scientists cautioned against oversimplifying the relationship between lifestyle and telomere length, the book succeeded in bringing telomere biology to a wide public audience and sparking broader interest in the science of aging.

In 2020, Sinclair's lab published a landmark paper in Nature demonstrating that a modified version of Yamanaka's reprogramming protocol could reverse aging in the eyes of elderly mice. Using three of the four Yamanaka factors -- OCT4, SOX2, and KLF4 (the "OSK" factors), deliberately omitting c-MYC due to its cancer-promoting potential -- the team showed that damaged retinal ganglion cells in aged mice could be rejuvenated. The treated mice regained youthful gene expression patterns and recovered lost vision.

Feng Zhang was born in 1981 in Shijiazhuang, the capital of Hebei province in northern China. At the age of eleven, he moved with his family to Des Moines, Iowa, where he quickly adapted to American life and developed a deep fascination with biology. In high school, Zhang participated in a gene therapy research program at the Methodist Hospital in Des Moines, working on green fluorescent protein (GFP) and viral vectors. This early exposure to molecular biology ignited a passion that would define his career.

The significance of iPSCs was immediately apparent. Embryonic stem cells had long been recognized as extraordinarily powerful -- capable of differentiating into any cell type, from neurons to heart muscle to insulin-producing beta cells. But obtaining them required the destruction of human embryos, which created profound ethical objections and political barriers, particularly in the United States, where federal funding for embryonic stem cell research was severely restricted under the Bush administration.

At UCSF, Kenyon built one of the premier aging research laboratories in the world. Her group continued to dissect the downstream targets of DAF-16, identifying hundreds of genes that contribute to longevity when the insulin pathway is suppressed. They discovered that the longevity effects of daf-2 mutations also depend on signals from reproductive tissue, suggesting that the body allocates resources between reproduction and self-maintenance -- a concept aligned with evolutionary theories of aging.

Demis Hassabis was a prodigy long before he entered the world of artificial intelligence. Born in London in 1976 to a Greek-Cypriot father and a Singaporean-Chinese mother, he became a chess master at age 13, ranking second in the world for his age group. He went on to study computer science at Cambridge, co-designed the legendary video game Theme Park at just 17, and earned a PhD in cognitive neuroscience from University College London, where he studied the neural basis of imagination and memory.

Zhang holds joint appointments at the Broad Institute and MIT's McGovern Institute for Brain Research, where he continues to explore the intersection of genome engineering and neuroscience. His contributions have earned him numerous awards, including the Canada Gairdner International Award, the Lemelson-MIT Prize, the Tang Prize in Biopharmaceutical Science, and the Harvey Prize. He was elected to the National Academy of Sciences and the National Academy of Inventors while still in his thirties.

At Temple University and then at the University of Pennsylvania, where she moved in 1989, Kariko devoted herself to developing mRNA as a therapeutic tool. The concept was straightforward in principle: if you could deliver synthetic mRNA into a patient's cells, those cells would produce whatever protein the mRNA encoded -- a vaccine antigen, a missing enzyme, a growth factor. Unlike gene therapy using DNA, mRNA would not integrate into the genome, reducing the risk of permanent genetic changes.

Rather than lock AlphaFold behind a paywall, Hassabis made the decision to open it up. In partnership with the European Bioinformatics Institute (EMBL-EBI), DeepMind released the AlphaFold Protein Structure Database, which eventually grew to contain predicted structures for over 200 million proteins — nearly every known protein in existence. The database was made freely available to researchers worldwide, and within its first year it was accessed by over a million scientists in 190 countries.

Charpentier's Nobel Prize-winning work began with an observation about Streptococcus pyogenes, the bacterium responsible for strep throat and flesh-eating disease. Scientists already knew that bacteria carried mysterious repetitive DNA sequences called CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) and that these sequences appeared to function as an immune memory system against viral invaders. But the molecular details of how the system actually worked remained murky.

Sickle cell disease is caused by a single mutation in the gene encoding beta-globin, a protein component of hemoglobin -- the molecule in red blood cells that carries oxygen throughout the body. The mutation causes hemoglobin molecules to clump together under low-oxygen conditions, distorting red blood cells into rigid, crescent-shaped "sickles." These misshapen cells clog blood vessels, blocking oxygen delivery and triggering episodes of excruciating pain known as vaso-occlusive crises.

Francisco Mojica was born in 1963 in Elche, a city in southeastern Spain known for its palm groves and Mediterranean climate. He studied biology at the University of Alicante, where he would spend virtually his entire career. For his doctoral research in the late 1980s and early 1990s, Mojica studied Haloferax mediterranei, a salt-loving archaeon (a type of single-celled organism distinct from bacteria) that thrives in the salt marshes and salterns near the coastal town of Santa Pola.

Since 2015, Charpentier has served as a director at the Max Planck Unit for the Science of Pathogens in Berlin, an institute created specifically for her. There, she continues to investigate the molecular mechanisms of bacterial infection and the biology of CRISPR systems. Her research extends beyond Cas9 to explore the diversity of CRISPR systems found across the microbial world, searching for new enzymes and mechanisms that may prove useful for future biotechnological applications.

Kelly's long-term vision is sweeping. He argues that biology will eventually replace chemical manufacturing across a wide range of industries, just as semiconductors replaced vacuum tubes. Microorganisms can be programmed to produce molecules that are currently synthesized through energy-intensive, pollution-generating chemical processes. Fermentation tanks can replace petrochemical plants. Living cells can serve as microscopic factories, running on sugar instead of petroleum.

Elizabeth Helen Blackburn was born in 1948 in Hobart, Tasmania, the island state off Australia's southern coast. She grew up fascinated by the natural world, collecting jellyfish and studying animals with a child's curiosity that would eventually mature into rigorous scientific inquiry. She attended the University of Melbourne, earning her bachelor's and master's degrees in biochemistry, before crossing the globe to pursue her PhD at the University of Cambridge in England.

Sirtuins are a family of enzymes (SIRT1 through SIRT7 in mammals) that regulate critical cellular processes including DNA repair, gene expression, metabolism, and inflammation. They require the coenzyme nicotinamide adenine dinucleotide (NAD+) to function, and NAD+ levels decline significantly with age. Sinclair's central hypothesis has been that this age-related decline in NAD+ impairs sirtuin function, contributing to the molecular deterioration that characterizes aging.

Endy has been the most prominent voice in synthetic biology arguing that the field's foundational tools and components should remain open and accessible. He has drawn explicit parallels to the open-source software movement, arguing that just as Linux and the World Wide Web flourished because their core components were free and open, synthetic biology will reach its full potential only if its basic building blocks are not locked behind patents and proprietary restrictions.

Sinclair has co-founded or been involved in more than a dozen biotech companies. Among the most recent is Tally Health, a consumer-facing company that offers biological age testing based on epigenetic clocks and provides personalized recommendations for slowing biological aging. The company represents Sinclair's vision of making longevity science accessible to ordinary consumers, though it has also raised questions about the commercialization of aging research.

After completing his PhD, Jumper joined DeepMind in 2017, just as the company was beginning to explore the protein folding problem in earnest. DeepMind, founded by Demis Hassabis, had already demonstrated the power of deep learning and reinforcement learning through AlphaGo and other projects. Hassabis had identified protein structure prediction as a scientific problem where AI could make a transformative contribution, and he was assembling a team to tackle it.

Emmanuelle Charpentier was born in 1968 in Juvisy-sur-Orge, a commune south of Paris. Growing up near the Institut Pasteur, she was drawn to science from an early age, inspired by the legacy of Louis Pasteur and Marie Curie. She studied biochemistry, microbiology, and genetics at the Pierre and Marie Curie University (now Sorbonne University) in Paris, earning her PhD in 1995 for work on antibiotic resistance mechanisms in the bacterium Listeria monocytogenes.

AlphaFold's impact on gene editing has been profound. CRISPR-Cas systems depend on precise protein-DNA interactions, and understanding the three-dimensional structure of Cas proteins is essential for engineering better gene editors. With AlphaFold, researchers can now model how Cas9, Cas12, and other editing proteins interact with their guide RNAs and target DNA, enabling the rational design of variants with improved specificity and reduced off-target effects.

Aubrey David Nicholas Jasper de Grey was born in 1963 in London, England. He studied computer science at the University of Cambridge, graduating in 1985, and spent several years working in the field of artificial intelligence research at the university. His pivot to biology was unconventional: he became interested in aging through his marriage to Adelaide Carpenter, a geneticist at Cambridge, and began reading voraciously about the biology of senescence.

Charpentier has also demonstrated a keen sense for translating science into medicine. In 2013, she co-founded CRISPR Therapeutics, a biotechnology company headquartered in Zug, Switzerland, and Cambridge, Massachusetts. The company became the first to bring a CRISPR-based therapy through regulatory approval when Casgevy (exagamglogene autotemcel) was authorized in 2023 for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.

Shinya Yamanaka was born in 1962 in Osaka, Japan. He studied medicine at Kobe University, drawn initially to orthopedic surgery. During his surgical residency, however, Yamanaka found himself struggling. Operations that experienced surgeons completed in thirty minutes took him hours. Colleagues nicknamed him "Jamanaka" -- a play on the Japanese word "jama," meaning obstacle. The experience was humbling, but it pointed Yamanaka toward a different path.

Google acquired DeepMind in 2014 for a reported 500 million dollars, giving Hassabis the resources to pursue his vision at scale. The first landmark came in 2016, when DeepMind's AlphaGo program defeated Lee Sedol, the world champion of Go — a game so complex that brute-force computation could never master it. The victory stunned the AI community and proved that deep reinforcement learning could tackle problems once thought to require human intuition.

The intersection of Yamanaka's reprogramming technology with modern gene editing tools like CRISPR creates extraordinary possibilities. Researchers can now take a patient's cells, reprogram them into iPSCs, use CRISPR to correct genetic mutations, and then differentiate the edited iPSCs into the desired cell type for transplantation. This combined approach is already being explored for diseases ranging from sickle cell anemia to Parkinson's disease.

One of the most frequently told stories about Kenyon involves her personal response to her own scientific findings. After discovering that the insulin signaling pathway controlled aging in worms, Kenyon dramatically altered her diet, cutting out sugar and refined carbohydrates. The reasoning was straightforward: these foods trigger insulin release in humans, and if high insulin signaling accelerates aging in worms, it might do the same in people.

Jason Kelly's journey begins at MIT, where he earned his PhD in biological engineering under the supervision of Tom Knight — widely regarded as one of the founding figures of synthetic biology. Knight, a veteran computer scientist who had turned to biology, was among the first to argue that living systems could be engineered with the same discipline applied to electronic circuits. His lab was a crucible for the ideas that would define the field.

Craig Venter's legacy is inseparable from the arc of synthetic biology itself. By demonstrating that genomes could be designed and built from chemical components, he established the foundational proof of concept for an entire discipline. Today, synthetic biologists designing engineered organisms, building gene circuits, and programming cells to produce medicines, materials, and fuels are all working in a tradition that Venter helped create.

The scientific establishment's response to SENS was mixed. A group of prominent biogerontologists published a critique in the EMBO Reports journal in 2005, arguing that several of the SENS proposals were speculative and not supported by sufficient evidence. De Grey responded vigorously, and the resulting debate raised the profile of aging research even as it highlighted genuine disagreements about the feasibility of specific interventions.

The heart of Ginkgo's operation is its Foundry — a massive, highly automated facility in Boston where robots and software manage the design, building, and testing of engineered organisms at a scale no academic lab could match. The Foundry runs millions of genetic experiments per year, using automated liquid handling, high-throughput screening, and machine learning to iterate through organism designs far faster than traditional approaches.

Yamanaka became the founding director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, an institution dedicated to translating iPSC technology into clinical therapies. Under his leadership, CiRA launched the world's first clinical trials using iPSC-derived cells, including a groundbreaking 2014 trial in which iPSC-derived retinal cells were transplanted into a patient with age-related macular degeneration.

In 2013, Zhang co-founded Editas Medicine, one of the first companies dedicated to developing CRISPR-based therapies. The company has pursued treatments for genetic eye diseases, blood disorders, and cancers, advancing several candidates into clinical trials. Though Zhang later stepped back from a direct operational role, Editas remains a testament to his vision of translating laboratory discoveries into treatments that reach patients.

Venter's path to science was anything but conventional. Born in Salt Lake City in 1946, he was an indifferent student who spent more time surfing than studying. At 21, he was drafted and served as a medic in the Vietnam War, an experience that profoundly shaped him. Surrounded by death and trauma in a field hospital in Da Nang, Venter developed a fierce urgency about life — and a determination to do something meaningful with his own.

AlphaFold's impact on gene editing has been direct and substantial. CRISPR-Cas gene editors are proteins, and understanding their three-dimensional structures is essential for improving their performance. With AlphaFold, researchers can model the structures of novel Cas proteins discovered in metagenomic surveys, predict how mutations will affect their activity and specificity, and design engineered variants with improved properties.

In 2019, Sinclair published "Lifespan: Why We Age -- and Why We Don't Have To," a bestselling book that brought his ideas to a general audience. The book argues that aging should be classified as a disease and treated with the same urgency as cancer or heart disease. Sinclair lays out his personal longevity regimen, which includes NMN (nicotinamide mononucleotide, an NAD+ precursor), resveratrol, metformin, and intermittent fasting.

Zhang's accomplishment quickly became the center of one of the most consequential intellectual property battles in the history of biotechnology. The Broad Institute, on behalf of Zhang, secured key patents covering the use of CRISPR-Cas9 in eukaryotic cells. The University of California, Berkeley, representing Jennifer Doudna, challenged these patents, arguing that their earlier in vitro work made the mammalian application obvious.

Building on the Cas13 discovery, Zhang and his collaborators developed SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing), a diagnostic platform capable of detecting minute quantities of viral or bacterial genetic material. SHERLOCK leverages the collateral cleavage activity of Cas13 -- when Cas13 finds its target RNA sequence, it begins indiscriminately cutting nearby RNA molecules, amplifying a detectable signal.

De Grey's public advocacy was relentless and effective. His 2005 TED talk, "A Roadmap to End Aging," has been viewed millions of times and remains one of the most influential presentations on longevity science ever delivered. In it, de Grey argued with characteristic bluntness that society's acceptance of aging as inevitable was not only scientifically unjustified but morally indefensible, given the scale of suffering it causes.

When the genetic sequence of SARS-CoV-2 was published in January 2020, the mRNA platform was ready. BioNTech, in partnership with Pfizer, and Moderna independently designed mRNA vaccines encoding the spike protein of the new coronavirus. Because mRNA vaccines require only the genetic sequence of the target -- not the virus itself -- the vaccines were designed within days and moved into clinical trials at unprecedented speed.

Jennifer Doudna grew up in Hilo, Hawaii, where the lush biodiversity of the Big Island sparked an early fascination with the natural world. As a child, she devoured books on science and was captivated when her father left a copy of James Watson's "The Double Helix" on her bed. That book -- a firsthand account of the discovery of DNA's structure -- ignited a lifelong passion for understanding the molecular machinery of life.

While the Nobel eluded him, Mojica has received numerous other honors. In 2017, he shared the Albany Medical Center Prize in Medicine and Biomedical Research -- one of the largest prizes in American medicine -- with Charpentier, Doudna, Zhang, and Luciano Marraffini. He has also received the Jaime I Prize in Basic Research, Spain's most prestigious science award, and has been elected to international scientific academies.

Aubrey de Grey's influence on longevity science is undeniable, even as his personal legacy is complicated. He was among the first public figures to articulate a coherent, comprehensive vision for treating aging as a medical condition. The SENS framework, Longevity Escape Velocity, and his tireless advocacy inspired thousands of researchers, entrepreneurs, and philanthropists to take aging seriously as a tractable problem.

Ginkgo's platform model attracted partnerships across industries. The company worked with Bayer on agricultural biologicals, engineering microbes that could protect crops or enhance soil health. It partnered with Roche subsidiary Genentech on mammalian cell engineering for drug production. It collaborated with Synlogic on living therapeutics — engineered bacteria designed to treat metabolic diseases from inside the gut.

Over the following years, Mojica discovered that similar repetitive sequences appeared in a wide variety of microbial genomes -- not just archaea, but also bacteria. Other researchers, including Japanese molecular biologist Yoshizumi Ishino, who had first inadvertently cloned such repeats from E. coli in 1987, had also noticed them, but no one had systematically cataloged their distribution or proposed a unifying name.

Cynthia Jane Kenyon was born in 1954 in Chicago, Illinois, and grew up in Georgia. She developed an early interest in science, drawn to the elegance of molecular biology at a time when the field was still relatively young. She earned her undergraduate degree in chemistry and biochemistry from the University of Georgia, then pursued her PhD at MIT, where she studied gene regulation under the mentorship of Graham Walker.

The treatment unfolded in several stages over the course of months. First, Victoria received injections of a drug called plerixafor combined with a growth factor to mobilize her blood stem cells from the bone marrow into the bloodstream, where they could be collected through a process called apheresis. The collected cells were shipped to a laboratory where CRISPR-Cas9 was used to edit the BCL11A gene in each stem cell.

Cynthia Kenyon's 1993 paper is one of the most cited in the history of aging research. It launched an entire subfield -- the genetics of longevity -- and attracted a generation of scientists to the study of aging mechanisms. Before her work, aging research was considered a backwater, underfunded and intellectually marginalized. After it, aging became one of the most dynamic and well-funded areas of biomedical science.

When the 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for "the development of a method for genome editing," many in the scientific community expressed dismay that Mojica was not included. The Nobel Prize can be shared by up to three recipients, and there was a strong case that Mojica's discovery of CRISPR's biological function was essential to everything that followed.

Doudna has been unusually forthcoming about the ethical dimensions of her discovery. In 2015, she co-organized the International Summit on Human Gene Editing at the National Academy of Sciences, bringing together scientists, ethicists, and policymakers to discuss the responsible use of CRISPR. She has publicly opposed the use of CRISPR for human germline editing until safety and ethical questions are resolved.

Victoria Gray's experience represents far more than a single patient's cure. It is a proof of concept for the entire field of CRISPR-based gene therapy. If a genetic disease caused by a single mutation can be effectively cured by editing a patient's own cells, then similar approaches may work for hundreds of other monogenic diseases -- from beta-thalassemia to muscular dystrophy to certain forms of blindness.

In 2011, Doudna attended a conference in Puerto Rico where she met Emmanuelle Charpentier, a French microbiologist studying Streptococcus pyogenes. Charpentier had been investigating CRISPR-associated proteins -- molecular tools that bacteria use to defend against viral infections by cutting up viral DNA. She had identified a key RNA molecule called tracrRNA that was essential for the system to function.

Jennifer Anne Doudna was born on February 19, 1964, in Washington, D.C., and grew up in Hilo, Hawaii. As a child, she was captivated by the natural world, from the tropical ecosystems around her to the molecular structures she encountered in books. When her father left a copy of James Watson's "The Double Helix" on her bed, it sparked a fascination with molecular biology that would define her career.

Endy's influence extends well beyond academia. He has advised DARPA's Living Foundries program, one of the largest government investments in synthetic biology, which aimed to develop tools for rapidly engineering biological systems for defense and industrial applications. The program helped establish many of the automated design-build-test workflows that now underpin commercial synthetic biology.

One of the most consequential decisions the team made — with strong support from both Jumper and Hassabis — was to open-source AlphaFold 2's code and make its predictions freely available. In partnership with EMBL-EBI, DeepMind released the AlphaFold Protein Structure Database, which grew to contain predicted structures for over 200 million proteins, covering nearly every known protein sequence.

The naming was important, but Mojica's most consequential insight came next. By the early 2000s, he had spent years systematically comparing the spacer sequences -- the unique DNA segments between the repeats -- against databases of known genomes. In 2003, he made a breakthrough: the spacers matched sequences from bacteriophages (viruses that infect bacteria) and other mobile genetic elements.

Two years later, AlphaFold 2 arrived at CASP14 and delivered one of the most stunning results in the history of computational biology. The system scored a median GDT (Global Distance Test) of 92.4 out of 100 — a level of accuracy that matched experimental methods. For many proteins, AlphaFold 2's predictions were essentially indistinguishable from structures determined in the laboratory.

No account of Craig Venter is complete without acknowledging the controversy that has trailed him throughout his career. Critics have called him a self-promoter who prioritized speed over rigor, a privatizer who tried to patent the common heritage of humanity, and an egotist who named his institute after himself and used his own DNA as the reference genome for Celera's sequencing effort.

Perhaps more than any other figure in the gene editing field, Doudna has championed ethical deliberation. After the 2018 revelation that Chinese scientist He Jiankui had used CRISPR to edit human embryos that were brought to term, Doudna was among the first prominent scientists to call for a global moratorium on heritable genome editing until appropriate safeguards could be established.

In 2014, Kenyon made a major career move, leaving UCSF to become Vice President of Aging Research at Calico, the secretive longevity research company established by Google co-founder Larry Page within the Alphabet corporate structure. Calico was launched with the ambitious goal of understanding the biology of aging and developing interventions that could extend healthy human lifespan.

In December 2023, the FDA approved Casgevy (exagamglogene autotemcel) for the treatment of sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises. It was the first CRISPR-based therapy to receive FDA approval for any condition -- a milestone that many considered the culmination of a decade of research that began with the 2012 Doudna-Charpentier paper.

Sinclair's career has been marked by recurring controversies. The resveratrol replication failures, the Cell retraction, and disagreements about the clinical significance of NAD+ supplementation have all generated criticism. Some prominent gerontologists have accused Sinclair of hype, arguing that his public statements create unrealistic expectations about near-term age reversal.

In 2021, de Grey's career took a sharp turn. Multiple women accused him of sexual harassment, including allegations of inappropriate behavior toward younger women affiliated with the SENS Research Foundation. An independent investigation commissioned by SRF substantiated several of the allegations. De Grey was removed from his positions at both SRF and the Methuselah Foundation.

Charpentier has spoken thoughtfully about the challenges women face in science, noting that systemic barriers -- from funding disparities to cultural biases -- continue to limit the participation and advancement of women in research. She has advocated for institutional changes that support work-life balance and create pathways for women to reach leadership positions in science.

In 2007, Philippe Horvath and Rodolphe Barrangou at the food science company Danisco (now part of DuPont) provided the first experimental proof that CRISPR is indeed an adaptive immune system, using Streptococcus thermophilus -- the bacterium used in yogurt production. Their work in Science confirmed Mojica's hypothesis and triggered an explosion of interest in CRISPR biology.

Having proved that synthetic genomes could work, Venter pursued a deeper question: what is the smallest set of genes needed to sustain life? By systematically stripping genes from the synthetic Mycoplasma genome, the JCVI team created syn3.0 in 2016 — a minimal cell with just 473 genes and 531,000 base pairs, making it the simplest self-replicating organism ever constructed.

Perhaps Endy's most far-reaching contribution has been the International Genetically Engineered Machine (iGEM) competition, which he co-founded in 2003 with Tom Knight and Randy Rettberg at MIT. What started as a small MIT course project has grown into the world's largest synthetic biology competition, with over 6,000 teams from more than 60 countries participating annually.

To make BioBricks useful, they needed to be cataloged and shared. Endy helped establish the Registry of Standard Biological Parts, hosted at MIT, which grew into one of the most important resources in synthetic biology. The Registry is an open, community-curated collection of thousands of BioBrick parts, each with documented sequences, functions, and assembly instructions.

Liu envisions a future where gene editing therapies are available for the thousands of genetic diseases that currently have no treatment. His lab continues to work on improving editing efficiency in hard-to-reach tissues, developing smaller editors that are easier to deliver via viral vectors, and creating new classes of editors that can make even larger genomic changes.

In 2003, Sinclair's lab published a paper in Nature reporting that resveratrol -- a compound found in red wine, grapes, and certain berries -- could activate SIRT1 and extend the lifespan of yeast. Follow-up studies suggested that resveratrol could also improve the health and lifespan of mice fed a high-fat diet, mimicking some of the benefits of caloric restriction.

The most tangible expression of Endy's vision was the BioBrick standard, introduced in the early 2000s. A BioBrick is a standardized DNA sequence — a promoter, a ribosome binding site, a coding sequence, a terminator — designed with defined flanking sequences so that any BioBrick can be physically assembled with any other BioBrick using a simple, universal protocol.

Jason Kelly occupies a unique position in synthetic biology. He is neither the field's most famous scientist nor its most celebrated inventor. What he has built is something different: the infrastructure. Ginkgo Bioworks is the factory floor of the synthetic biology revolution — the place where engineered organisms go from concept to reality at industrial scale.

Doudna studied biochemistry at Pomona College and earned her Ph.D. at Harvard Medical School under Jack Szostak, who would later win his own Nobel Prize for work on telomeres. Her doctoral research focused on ribozymes -- RNA molecules that can catalyze chemical reactions, challenging the prevailing view that only proteins could serve as biological catalysts.

Kenyon's discovery was not merely a curiosity of worm biology. The insulin/IGF-1 signaling pathway is one of the most ancient and conserved molecular circuits in the animal kingdom. Variants of daf-2 and DAF-16 exist in flies, mice, and humans. Studies in other organisms quickly confirmed that reducing insulin/IGF-1 signaling extends lifespan across species:

The researchers who did pay attention were entrepreneurs. In 2013, Kariko was recruited by Ugur Sahin and Ozlem Tureci, the founders of BioNTech, a German biotechnology company focused on developing mRNA-based cancer immunotherapies. Kariko became BioNTech's Senior Vice President, bringing her expertise in modified nucleosides to the company's mRNA platform.

By the mid-1980s, Hungary's economy was struggling, and Kariko's research funding was eliminated. She and her husband, Bela Francia, made the decision to leave for the United States, where she had secured a postdoctoral position at Temple University in Philadelphia. But Hungarian law severely restricted how much money citizens could take out of the country.

From the beginning, Ginkgo positioned itself not as a company that made any single product, but as a platform — "the organism company." The idea was to build a general-purpose cell programming facility that could engineer microorganisms for any client and any application: fragrances, flavors, pharmaceuticals, agriculture, industrial chemicals, and beyond.

Yamanaka maintained a parallel laboratory at the Gladstone Institutes in San Francisco throughout his career, fostering a unique bridge between Japanese and American stem cell research. His dual-continent presence helped accelerate the global adoption of iPSC technology and ensured cross-pollination between two of the world's leading research ecosystems.

In 2016, Liu and his postdoctoral researcher Alexis Komor published a landmark paper in Nature describing the first base editor. The concept was ingenious: take a catalytically impaired Cas9 protein that can find a specific DNA sequence but cannot cut both strands, and fuse it to a deaminase enzyme that can chemically convert one DNA base into another.

In 2019, Victoria learned about a clinical trial being conducted by Vertex Pharmaceuticals and CRISPR Therapeutics at the Sarah Cannon Research Institute in Nashville, Tennessee. The trial, known as CTX001 (later renamed Casgevy), was testing whether CRISPR-Cas9 gene editing could cure sickle cell disease by modifying a patient's own blood stem cells.

Hassabis did not stop at proteins. In 2024, DeepMind released AlphaFold 3, which extended the system's capabilities to predict the structures of complexes involving proteins, DNA, RNA, and small molecules. This was a critical advance, because most biological processes involve interactions between multiple types of molecules, not proteins in isolation.

Sinclair's most ambitious theoretical contribution is what he calls the Information Theory of Aging. The core idea is that aging is not primarily caused by genetic mutations but by the loss of epigenetic information -- the chemical modifications and structural changes to DNA and histones that determine which genes are turned on or off in each cell.

Victoria's transformation made her not only a medical success story but also an advocate. In 2023, she testified before the United States Senate, describing her experience with sickle cell disease and her treatment with CRISPR. Her testimony was a powerful argument for the potential of gene therapy and for equitable access to these new treatments.

After more than a year of rejections, Mojica's paper was finally accepted by the Journal of Molecular Evolution and published in February 2005. Independently, a French group led by Alexander Bolotin and a team led by Christine Pourcel reached similar conclusions around the same time, with Pourcel's paper appearing in Microbiology in March 2005.

David R. Liu was born in 1973 in Riverside, California. He showed extraordinary academic talent early, graduating from Harvard College summa cum laude in 1994 with a degree in chemistry. He earned his PhD in organic chemistry from UC Berkeley in 1999 under the mentorship of Peter Schultz, where he worked on expanding the genetic code.

When the COVID-19 pandemic hit in 2020, Ginkgo pivoted rapidly to biosecurity. The company launched a massive testing operation, processing millions of COVID tests for schools, workplaces, and government agencies. It also spun out Concentric by Ginkgo, a biosecurity division focused on pathogen monitoring and early warning systems.

Katalin Kariko was born in 1955 in Kisujszallas, a small town on the Great Hungarian Plain. Her father was a butcher, and the family lived modestly in a home without running water, a refrigerator, or a television. Despite these humble circumstances, Kariko excelled academically and developed a passion for biology at an early age.

When AlphaFold 2 entered CASP14 in November 2020, the results were extraordinary. The system achieved a median GDT score of 92.4, with many predictions essentially indistinguishable from experimentally determined structures. On some targets, AlphaFold 2's predictions were more accurate than low-resolution experimental structures.

The turning point came through a chance encounter. In 1997, Kariko met Drew Weissman, an immunologist at UPenn, while they were both using the departmental copy machine. Weissman was interested in developing an HIV vaccine and was intrigued by the possibility of using mRNA to deliver antigens. He and Kariko began collaborating.

For her postdoctoral work, Blackburn moved to Yale University, where she joined the laboratory of Joseph Gall. Her project involved sequencing the chromosome ends of Tetrahymena thermophila, a single-celled pond organism with an unusual genome: it contains thousands of tiny chromosomes, each with two ends that need protection.

In 2003, de Grey co-founded the Methuselah Foundation with David Gobel, initially focused on the Methuselah Mouse Prize -- an award for researchers who could extend the lifespan of laboratory mice. The prize generated publicity and attracted interest from researchers who might not otherwise have considered working on aging.

In 2017, Doudna co-founded Mammoth Biosciences, a company focused on developing CRISPR-based diagnostics and therapeutics. Mammoth has leveraged the discovery of novel Cas proteins, including ultra-compact Cas14 (now called Cas-phi) proteins, which are small enough to be delivered via adeno-associated virus (AAV) vectors.

The implications of Blackburn's discoveries extended far beyond basic biology. If telomere shortening limits the number of times a cell can divide, then telomere length functions as a kind of biological clock -- a molecular timer for cellular aging. This insight connected telomere biology directly to the science of aging.

Every two years, the protein structure prediction community holds a competition called CASP (Critical Assessment of protein Structure Prediction), in which teams attempt to predict the structures of proteins whose shapes have been experimentally determined but not yet published. For decades, progress had been incremental.

The results exceeded expectations. Within months, Victoria's fetal hemoglobin levels rose dramatically. Before treatment, her fetal hemoglobin was negligible -- as is typical for adults. After treatment, fetal hemoglobin constituted roughly half of her total hemoglobin, far above the threshold needed to prevent sickling.

In 2014, Doudna founded the Innovative Genomics Institute (IGI) at UC Berkeley, later expanding it as a joint initiative with UC San Francisco. The IGI's mission is to translate CRISPR discoveries into practical applications that benefit society. Under Doudna's leadership, the institute has pursued projects spanning:

Drew Endy trained as a civil and environmental engineer before turning to biology, and that engineering sensibility has defined his entire career. After completing his PhD at Dartmouth, he joined MIT's biological engineering faculty, where he became one of the founding voices of synthetic biology in the early 2000s.

Returning to Japan, Yamanaka took a faculty position at the Nara Institute of Science and Technology. The work was grueling and underfunded. He later described this period as deeply challenging, admitting that he nearly abandoned research altogether. But the question of cellular identity kept pulling him forward.

Between his genome sequencing and synthetic biology work, Venter embarked on one of the most ambitious environmental genomics projects ever attempted. From 2003 to 2007, he sailed his yacht Sorcerer II around the world, collecting ocean water samples every 200 miles and sequencing the microbial DNA within them.

The AlphaFold team's first major test came at CASP13 in 2018. AlphaFold 1 used deep neural networks to predict distances between pairs of amino acids, then used gradient descent to find 3D structures consistent with those predictions. The system won the competition convincingly, outperforming all other entries.

In September 2021, Ginkgo went public through a merger with a special purpose acquisition company (SPAC), valuing the company at approximately 15 billion dollars at its peak. The IPO made Ginkgo the most valuable pure-play synthetic biology company in the world and brought unprecedented attention to the field.

In later years, Blackburn became president of the Salk Institute for Biological Studies in La Jolla, California, where she championed research at the intersection of aging, genetics, and neuroscience. Her tenure at the Salk further cemented her role as one of the most influential biologists of her generation.

Church was instrumental in launching the Human Genome Project in 1984 — the ambitious effort to read the entire human genetic code. He developed some of the earliest methods for DNA sequencing, including the concept of direct sequencing with fluorescent labels that became the foundation for modern genomics.

Liu's contributions have earned him numerous accolades. He has been named to the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He has received the Breakthrough Prize in Life Sciences, the NAS Award in Chemical Sciences, and the Solvay Prize.

Blackburn spent the bulk of her career at the University of California, San Francisco (UCSF), where she chaired the Department of Microbiology and Immunology. Her laboratory continued to explore telomere biology, investigating how stress, lifestyle, and psychological factors influence telomere length.

John Jumper's road to DeepMind wound through physics, not biology. He earned his undergraduate degree at Vanderbilt University, where he studied physics and mathematics, developing the kind of rigorous quantitative foundation that would later prove essential for attacking the protein folding problem.

At a microbiology conference in Puerto Rico in 2011, Charpentier met Jennifer Doudna, a structural biologist at the University of California, Berkeley, who had deep expertise in RNA biology. The two scientists recognized that their complementary skills could crack the CRISPR-Cas9 system wide open.

Proteins are the molecular machines of life. They start as simple chains of amino acids, then fold into intricate three-dimensional shapes that determine their function. Understanding a protein's structure is essential for understanding how it works — and for designing drugs that interact with it.

The turning point came in 2011 when Doudna met Emmanuelle Charpentier, a French microbiologist, at a scientific conference in Puerto Rico. Charpentier had been studying a small RNA molecule called tracrRNA that played a critical role in the CRISPR immune system of Streptococcus pyogenes bacteria.

Jennifer Doudna's impact extends far beyond a single publication. She transformed molecular biology by making precise gene editing accessible to researchers worldwide, catalyzed a multibillion-dollar biotechnology industry, and set a standard for scientific leadership on ethical questions.

De Grey's most important intellectual contribution is SENS: Strategies for Engineered Negligible Senescence. First articulated in detail in the early 2000s, SENS is a framework that categorizes the damage of aging into seven distinct types and proposes specific repair strategies for each:

In 2022, Yamanaka joined Altos Labs, a biotechnology company backed by billions of dollars from investors including Yuri Milner and Jeff Bezos. Altos Labs is pursuing what may be the most ambitious goal in the history of biology: the reversal of aging through cellular reprogramming.

Drew Endy did not create the first synthetic organism or win a Nobel Prize. His legacy is different and arguably just as important: he established the principles that allow synthetic biology to function as an engineering discipline. Standardization. Modularity. Openness. Community.

Over the next two years, Jumper led the design and development of AlphaFold 2, a ground-up reimagination of the system. The key innovation was the Evoformer, a novel neural network architecture that Jumper and his collaborators designed specifically for the protein folding problem.

In 1998, Venter made one of the boldest bets in the history of science. He founded Celera Genomics and announced that he would sequence the entire human genome faster and cheaper than the publicly funded Human Genome Project (HGP), which had been working on the problem since 1990.

Kenyon joined the faculty at UCSF in 1986 and began studying the genetics of development in C. elegans. Her pivot to aging research came from a simple but radical question: if genes control development, growth, and reproduction, might they also control how long an organism lives?

In 1984, Blackburn began a collaboration that would change the course of biology. Carol Greider, a graduate student in Blackburn's laboratory at the University of California, Berkeley, set out to find the enzyme responsible for adding telomeric repeats to chromosome ends.

Base editing was transformative, but it was limited to four specific types of base-to-base conversions. Many genetic diseases involve other types of mutations, including insertions, deletions, and all 12 possible point mutations. Liu wanted something more versatile.

George Church is a renowned professor at Harvard and MIT who stands at the forefront of the genetic revolution. His journey, spanning over four decades, has been marked by groundbreaking contributions that continue to shape the future of genetics and biotechnology.

After leaving Celera in 2002, Venter turned to an even more ambitious goal: creating life from scratch. He founded the J. Craig Venter Institute (JCVI), a nonprofit research organization dedicated to genomic research, and set about building a synthetic genome.

Zhang has never been content to rest on a single discovery. In the years following his landmark Cas9 paper, he has systematically expanded the CRISPR toolkit, discovering and characterizing new enzymes that address limitations of the original system.

In October 2020, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry "for the development of a method for genome editing." They were the first two women to share a Nobel Prize in science without a male co-laureate.

In 2005, Church launched the Personal Genome Project (PGP), one of the first open-access human genome databases. The project aimed to sequence the genomes of 100,000 volunteers and make the data publicly available — a radical idea at the time.

In June 2012, Doudna, Charpentier, and their colleagues published a landmark paper in the journal Science titled "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity." The paper demonstrated three critical findings:

The significance of Kariko's work extends far beyond vaccines. Modified mRNA is now being developed as a delivery mechanism for an extraordinary range of therapeutic applications:

Liu's inventions quickly attracted commercial interest. He co-founded two major companies to translate these technologies into medicines:

To understand Liu's contribution, it helps to think of gene editing technologies as a spectrum of precision:

Church envisions a future where gene editing becomes as routine as vaccination. His current research spans: